Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- International Price Comparisons of Psychiatric Drugs
- Overview
- Antidepressants
- Antipsychotics
- Psychostimulants
- Hypnotics, Sedatives, and Anxiolytics
- Reimbursement Environment
- United States
- General Environment
- Private Insurance
- Medicare
- Sidebar: Patient Assistance Programs-An Important Source of Drug Funding
- Medicaid
- Antidepressants
- Antipsychotics
- Psychostimulants
- Hypnotics, Sedatives, and Anxiolytics
- France
- General Environment
- Antidepressants
- Antipsychotics
- Psychostimulants
- Hypnotics, Sedatives, and Anxiolytics
- Germany
- General Environment
- Antidepressants
- Antipsychotics
- Psychostimulants
- Hypnotics, Sedatives, and Anxiolytics
- Italy
- General Environment
- Antidepressants
- Antipsychotics
- Psychostimulants
- Hypnotics, Sedatives, and Anxiolytics
- Spain
- General Environment
- Antidepressants
- Antipsychotics
- Psychostimulants
- Hypnotics, Sedatives, and Anxiolytics
- United Kingdom
- General Environment
- Antidepressants
- Antipsychotics
- Psychostimulants
- Hypnotics, Sedatives, and Anxiolytics
|
Related Report
|
View Cart
